

# 11

Express Mail Label No. EL302645404US



PATENT  
Attorney Docket No. LEX-003

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S): Gillies *et al.*

SERIAL NUMBER: 09/256,156

GROUP NUMBER: 1644

FILING DATE: February 24, 1999

EXAMINER: J. Murphy

TITLE: ENHANCING THE CIRCULATING HALF LIFE OF  
ANTIBODY-BASED FUSION PROTEINS

**RESPONSE TO RESTRICTION REQUIREMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:


In the Office Action mailed from the U.S. Patent Office on April 10, 2000 for the above-identified patent application, the Examiner requires Applicants to restrict prosecution to one of two Groups of claims, each Group being said to recite a distinct invention. Specifically, Group I comprises claims 1-13 and 25, and Group II comprises claims 14-24 and 26.

Applicants provisionally elect, with traverse, to prosecute the invention of Group I (claims 1-13 and 25) directed to "an antibody-based fusion protein with an enhanced circulating half-life, classified in class 530, subclass 387.3."

Response to Restriction Requirement  
U.S. Serial No. 09/256,156  
Page 2

If the Examiner believes a conversation with Applicants' agent would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned agent at (617) 248-7240.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Pat R.H. Waller". The signature is fluid and cursive, with the first name "Pat" being more prominent.

Patrick R.H. Waller  
Registration No. 41,418

Dated: June 12, 2000

TESTA, HURWITZ & THIBEAULT, LLP  
High Street Tower  
125 High Street  
Boston, MA 02110

Tel: (617) 248-7240  
Fax: (617) 248-7100

1014561